Peptide evidence review

What the research actually shows about CJC-1295

In healthy adults, the with-DAC form of CJC-1295 reliably raises growth hormone and IGF-1 for several days after a single injection. That is a real biomarker effect, and it is the only thing the human evidence actually shows. No controlled human trial has tested it for muscle, fat, recovery, sleep, or aging; the body-composition data come from growth-hormone-deficient mice; the form most people buy is the no-DAC version, which has no human pharmacology data of its own; and in the only multi-month patient program, halted in 2006, a participant died of a heart attack the trial physician attributed to pre-existing heart disease and judged unrelated, a cause that was never independently confirmed.

The honest read

The honest summary of CJC-1295 is short. In healthy adults, a single injection of the with-DAC form reliably lifts growth hormone and IGF-1 for several days, and that part is real and replicated. What it is not is a measured benefit. Higher growth-hormone and IGF-1 readings on a lab report are not more muscle, less fat, better sleep, faster recovery, or slower aging, and no controlled human trial has tested CJC-1295 for any of those outcomes. A hormone level moving is the whole of the human evidence.

The rest of the honest read is sobering. CJC-1295 has never been approved by the FDA, its developer halted clinical work in 2006, and the only time it was given to patients for months rather than to volunteers for weeks, that program was stopped after a participant died of a heart attack. That death has to be stated without spin in either direction: the trial physician attributed it to pre-existing, asymptomatic coronary artery disease and judged it unrelated to the drug, and that attribution was never independently confirmed. It is not evidence that CJC-1295 is safe, and it is not evidence that CJC-1295 causes death. The muscle and body-composition data come from growth-hormone-deficient mice. And there is a distinction almost every buyer misses: the version studied in those human trials is the with-DAC form, while the version most people actually buy is the no-DAC "modified GRF 1-29," which has no published human pharmacology of its own. For any athlete subject to testing, CJC-1295 is banned at all times and detectable by validated assays.

This piece grades each claim by the strength of the evidence behind it, separates what was shown in people from what was shown in animals, distinguishes the two compounds sold under one name, and surfaces the safety and regulatory status you would want before any conversation with a clinician.

What CJC-1295 is and how it is thought to work

CJC-1295 is a synthetic, long-acting analog of growth-hormone-releasing hormone (GHRH), the natural signal your hypothalamus uses to tell the pituitary gland to release growth hormone. It is a secretagogue: rather than supplying growth hormone directly, it prompts your own pituitary to release more of it, which in turn drives the liver to make IGF-1 (Frohman and Kineman 2002). It is built on the active fragment of human GHRH and acts at the same receptor (Jetté et al. 2005).

The reason CJC-1295 exists at all is a pharmacokinetic trick. Natural GHRH lasts only minutes in the bloodstream before enzymes break it down, which makes it useless as a once-in-a-while injection. CJC-1295 adds a chemical group, the "DAC" or Drug Affinity Complex, that lets the peptide bind covalently to albumin, the most abundant protein in your blood, right after injection. Tethered to albumin, it evades rapid clearance, and its half-life stretches from minutes to roughly six to eight days, long enough for a single dose to keep growth hormone elevated for days (Teichman et al. 2006).

Here is the distinction that almost every buyer misses, and it is load-bearing. There are two different compounds sold under the name "CJC-1295." The version with DAC is the one ConjuChem developed and the only one ever studied in a human dosing trial. The version without DAC, widely sold as "modified GRF 1-29," lacks the albumin-binding group, is short-acting, and has no published human pharmacology study at all. Almost everything quantitative and human in this article describes the with-DAC form. The form most clinics and websites actually sell is usually the no-DAC version, the less-studied of the two. If you do not know which one you are looking at, you do not know whether any of the human data applies.

For a reader, the practical consequence is blunt. When you see "CJC-1295" on a product page or a forum thread, you usually cannot tell from the name alone which of the two molecules it is, and they behave differently in the body. Any claim that leans on the human half-life or the multi-day duration is a claim about the with-DAC form; if what you actually have is the no-DAC "modified GRF 1-29," those numbers do not describe it.

What the research actually shows, graded by evidence tier

Here is the split that matters most, stated plainly. Strip out the large body of anti-doping detection papers, where CJC-1295 is just a substance an assay is designed to catch, and the genuine pharmacology evidence is small. There are three published human studies, all in healthy adults, all small, and all measuring hormone levels rather than health outcomes. The body-composition evidence is entirely in growth-hormone-deficient rodents. There is no controlled human trial of any clinical, performance, or cosmetic outcome for CJC-1295, and the one multi-month patient program was halted and never published.

The pharmacology is genuinely interesting. The clinical case in humans does not exist yet. The sections below walk each use case at its own tier.

It is worth naming the gap directly: CJC-1295's popularity vastly exceeds its evidence. It is sold and discussed as a physique and anti-aging tool, and the controlled human record behind it is three small studies of a hormone level. That mismatch, between how much is claimed and how little has actually been measured, is the single most important thing to carry into any decision about it.

Growth hormone and IGF-1: the one thing with human evidence

This is the best-supported finding, and it is important to say exactly what it is. In two randomized, placebo-controlled, ascending-dose trials in healthy adults, a subcutaneous dose of CJC-1295 with DAC produced dose-dependent increases in growth hormone of roughly two- to ten-fold for at least six days and IGF-1 of about one-and-a-half- to three-fold for nine to eleven days, with effects accumulating over repeated doses (Teichman et al. 2006). A separate small study in healthy men found that CJC-1295 raised baseline growth hormone while preserving the natural pulsatile rhythm of its release (Ionescu and Frohman 2006), and a third confirmed the downstream activation of the growth-hormone and IGF-1 axis through changes in blood-protein profiles (Sackmann-Sala et al. 2009).

What none of these studies show is a benefit. Every one measured a hormone level in a healthy volunteer; none measured muscle, fat, strength, sleep, recovery, or any health endpoint, and the subjects had nothing wrong with them to improve. A rise in growth hormone and IGF-1 is a biomarker movement. The leap from "raises IGF-1" to "improves health" is the move the marketing makes and the evidence does not.

Muscle, fat, and body composition: rodent deficiency-rescue only

No controlled human trial has ever tested CJC-1295 for muscle mass, strength, or body fat. The only body-composition evidence comes from mice that were genetically engineered to be growth-deficient: in those animals, CJC-1295 normalized body weight and lean and fat mass and rescued growth (Alba et al. 2006; Gautam et al. 2009). Read what that means carefully. These are correction-of-deficiency experiments in animals that were deficient to begin with. Restoring normal growth in a deficient mouse says nothing about adding the compound to a healthy, hormonally normal adult to build muscle or lose fat. Independent 2026 clinical reviews say so directly, classing CJC-1295's musculoskeletal evidence as limited to animal studies with indications and dosing unknown (Mayfield et al. 2026; Villegas Meza et al. 2026).

One point of frequent confusion deserves a flag. Visceral-fat reduction has genuinely been shown in large human trials, but for a different, FDA-approved GHRH analog called tesamorelin, not for CJC-1295 (Falutz et al. 2010). The two are not interchangeable. Tesamorelin's evidence cannot be borrowed to support CJC-1295, which has no comparable human outcome data of its own.

Anti-aging, recovery, sleep, and performance: not tested

No human study has tested CJC-1295 for any aging endpoint, for recovery, for sleep quality, or for athletic performance. In recent reviews it appears only as an investigational compound with limited clinical evidence and no long-term safety data (Mavrych et al. 2026; Renke and Chinellato 2026), and sports-medicine reviews place it in the experimental, gray-market category, flagging placebo effects and social-media amplification as reasons perceived benefits should be discounted (Mendias and Awan 2026; Coutinho et al. 2026). The reports of better sleep or younger-looking skin that circulate online come from user communities, not from controlled studies (Van Hout and Hearne 2016). The "higher IGF-1 means younger" logic is a hypothesis, and a chronically elevated IGF-1 level is itself a theoretical risk rather than a proven benefit.

The CJC-1295-and-ipamorelin pairing: popular, never tested as a combination

The near-universal real-world practice is to combine CJC-1295 with ipamorelin, a separate growth-hormone secretagogue, on the theory that the two produce a larger, more natural growth-hormone release together. It is worth being precise: no human trial has ever tested that combination. The reviews that mention the pairing cite only single-agent animal data (Mayfield et al. 2026). The popularity of the combination is a clinic-and-community convention, not a protocol validated in any human study, and the fact that two compounds are commonly used together is not evidence that doing so is effective or safe.

Safety, the 2006 trial, and what we don't know

The honest framing on safety begins with how thin the human record is. In the controlled studies, which lasted weeks in healthy volunteers, the most common side effects were injection-site reactions such as transient pain, swelling, and redness, and no serious adverse reactions were reported (Teichman et al. 2006). That sounds reassuring until you note its limits: those studies were short, small, in healthy people, and not designed to detect longer-term or rare risks.

The single most consequential safety data point comes from the one time CJC-1295 was given to patients over months. In a 2006 phase-2 trial of the with-DAC form in roughly 192 patients with HIV-associated lipodystrophy, one participant died of a heart attack about two hours after their 11th weekly injection, and the program was stopped (U.S. Food and Drug Administration docket presentation; aidsmap 2006). This needs to be stated without spin in either direction. The trial physician attributed the death to pre-existing, asymptomatic coronary artery disease and judged it unrelated to CJC-1295. That attribution was never independently confirmed in the published literature, and no efficacy or safety results from that program were ever published. It is not evidence that CJC-1295 causes heart attacks, and it is equally not something to omit: a death occurred, the cause was attributed to pre-existing heart disease, causality was never independently established, and the only multi-month program in the compound's history was halted.

Beyond that, the risks are mechanism-based and unquantified. Because CJC-1295 chronically raises growth hormone and IGF-1, the theoretical concerns are the familiar growth-hormone-excess profile: insulin resistance, fluid retention, joint aches, and, as a longer-term theoretical worry, the proliferative and cancer-related risks associated with sustained high IGF-1 (Frohman and Kineman 2002). None of this has been measured for CJC-1295 specifically, because no long-term human study exists; that absence is the point, not a clean bill of health. Recent reviews add cardiovascular and metabolic strain as class concerns, especially at the higher, stacked doses common outside trials (Coutinho et al. 2026).

The cancer question deserves to be stated plainly rather than buried in a list, because it is the reason the "more IGF-1 is younger" pitch cuts both ways. IGF-1 is a growth signal, and chronically raising a growth signal is exactly the kind of exposure that warrants caution in anyone with a personal or family history of cancer. No study has shown that CJC-1295 causes cancer, and none has shown it is safe on that axis either, because the long-term human studies that could answer the question were never done. For a decision about your own body, an honest "we don't know" should weigh heavily.

There is also a safety axis that has nothing to do with the molecule and everything to do with the market. Because no approved product exists, the CJC-1295 sold to the public is unapproved, often illicitly manufactured, and has been found mislabeled or in preparations of unknown identity (Henninge et al. 2010); reviews repeatedly cite product quality and contamination as a primary hazard independent of the drug's intrinsic pharmacology (Mendias and Awan 2026). And because there is no regulated label, there are no established contraindications or drug-interaction data; active or prior cancer and any other growth-hormone-modulating therapy are obvious caution areas by mechanism, not from CJC-1295-specific evidence. There is no validated human dose for any consumer use; the figures that appear in studies were research doses in monitored trials, not guidance.

FDA status and anti-doping (WADA) status

Start with where CJC-1295 actually stands, legally and in sport, because most pages gloss right over it.

First, FDA status: CJC-1295 has never been approved by the FDA for any use. It was an investigational compound whose development was halted in 2006, and current clinical reviews describe it as an unapproved, gray-market peptide sold direct to consumers outside regulatory oversight (Mendias and Awan 2026; Mayfield et al. 2026). It appears in an open FDA docket evaluating bulk substances for compounding, but the precise, current federal compounding category is unsettled and we are deliberately not asserting a specific one as fact; the durable, verified statement is that CJC-1295 is not an FDA-approved medicine and is not an established legal compounding substance. It is worth contrasting it with tesamorelin, the GHRH analog that is FDA-approved and backed by phase-3 trials (Falutz et al. 2010): that is what "approved and evidenced" looks like, and CJC-1295's record never approached it.

Second, anti-doping status: CJC-1295 is named explicitly on the World Anti-Doping Agency Prohibited List under Section S2, in the growth-hormone-releasing-factors sub-class, and is prohibited at all times, in and out of competition (World Anti-Doping Agency; Henninge et al. 2010). It is also detectable: there is an extensive, validated body of anti-doping assays built specifically to catch it and related analogs (Memdouh et al. 2021; Pont et al. 2020). Any athlete subject to anti-doping rules who uses CJC-1295 commits a violation, and the idea that it is undetectable is false. This belongs prominently in front of anyone who competes.

How and when to think about using CJC-1295

Vague "ask your doctor" is not useful, so here is the specific version, and for CJC-1295 the specific version starts with an honest hard stop. There is no approved, evidence-based dose, because no human trial ever tested CJC-1295 for a benefit, only for what it does to a hormone level. Every dose, schedule, and stack you will see quoted comes from clinic and community practice, not from anything that measured whether it works or is safe over time. We are not going to hand you a protocol the evidence does not support. What we can do is lay out how to think about the decision, and report, in the next section, what is actually done, so you are deciding with open eyes rather than from a vendor's pitch.

The decision factors are the ones already on this page, lined up. The upside is biomarker-grade and nothing more: in healthy adults the with-DAC form raises growth hormone and IGF-1 for several days, and not one controlled human study shows that this turns into muscle, fat loss, recovery, sleep, or slower aging. The form question is real: the human numbers describe the with-DAC version, but the no-DAC "modified GRF 1-29" is what most clinics and sites actually sell, and its human pharmacology is uncharacterized, so you often cannot tell from the label whether any of the data even applies to what is in the vial. The safety is unknown over any meaningful timeframe, because the only multi-month program in the compound's history was halted, and it was halted after a death the trial physician judged unrelated but no one independently confirmed. The mechanism itself carries unquantified hormone-excess concerns, insulin resistance, fluid retention, joint aches, and the theoretical proliferative risk of chronically raising IGF-1. The supply is unregulated and frequently mislabeled. And the sport status is settled and against use: named on the WADA list and detectable.

Some "when not" answers are clear enough to state plainly. If you have any personal or family history of heart disease, the cardiac death in the halted trial, even with its cause attributed to pre-existing disease, is reason to be especially cautious rather than reassured. If you have a personal or family history of cancer, chronically raising a growth signal like IGF-1 is exactly the kind of exposure to avoid. If you are subject to anti-doping testing, this is a named, detectable, banned substance and the answer is no. If you cannot verify what is actually in the vial, and which form it is, with a batch-specific certificate of analysis, you are dosing an unknown. And if you are pregnant or breastfeeding, there is no safety data and no reason to assume any.

If, knowing all of that, you still want to understand what real-world use looks like, the next section reports it, with the risks named and without a recommendation attached.

What people and clinics actually do with CJC-1295 (and what we can't tell you)

The line that governs everything below: there is no approved clinical dose for CJC-1295, and no human trial has ever tested a dose, a schedule, or a stack for any benefit. Everything in this section is what people report doing in community forums and what some clinics publish. It is not a recommendation, it has not been validated, and it is the weakest tier of evidence on this page. We include it because pretending the real-world use doesn't exist doesn't make anyone safer. Understanding it, with the risks named, does.

Which form people use, and the dose that goes with it. The form most people actually buy and inject is the no-DAC version, "modified GRF 1-29," not the with-DAC form the human studies used. For that no-DAC form, the reported pattern is fairly consistent: roughly 100 micrograms per injection, by subcutaneous injection, often before bed on an empty stomach, on the theory of amplifying the body's natural overnight growth-hormone pulse, once to a few times a day. The with-DAC form is reported differently because of its multi-day half-life, larger doses of roughly one to two milligrams given once or twice a week, though that figure leans heavily on vendor literature with fewer first-hand reports behind it. Cycles of several weeks to a few months, with breaks, circulate for both. Read those numbers as community convention, not as a tested protocol.

The stack. The near-universal real-world practice is to combine CJC-1295 with ipamorelin, a separate growth-hormone secretagogue, drawn into the same syringe and injected together, on the theory that hitting two different receptors produces a larger growth-hormone release than either alone. State this plainly: that pairing is a clinic and community convention, not a combination validated in any human trial. No controlled human study has ever tested CJC-1295 with ipamorelin, and the reviews that mention the pairing cite only single-agent animal data. That two compounds are commonly used together is not evidence that doing so is effective or safe.

What the community itself flags. The forums are not naive about the risks. The historical trial death is widely known and is repeatedly invoked as the reason continuous, saturating growth-hormone stimulation is treated cautiously. Beyond that, the most-cited side effects are water retention, which some report easing after a few weeks; injection-site reactions and transient flushing; and rising blood sugar or insulin resistance over time, with monitoring advised. With the with-DAC form specifically, the worry raised is that its sustained elevation may blunt the body's natural pulsatile rhythm, which is part of why some users prefer the shorter-acting no-DAC form. And as with any gray-market peptide, experienced users treat source quality as a primary risk and demand batch-specific third-party purity testing.

What we can't tell you, honestly. Several cautions about the numbers above. We could not read the primary forum threads directly, because Reddit blocks automated access, so these figures come through secondary write-ups that summarize those threads. A large share of the clinic protocols online are published by peptide-selling and wellness-marketing sites that repeat each other's numbers, so the apparent agreement is partly an echo chamber, not independent confirmation. The source landscape is muddied further by a specific confusion: clinic content routinely quotes the with-DAC half-life of six to eight days while prescribing daily pre-bed dosing, which only makes sense for the no-DAC form, so the two molecules are frequently conflated in the very material people rely on. We also found vendor pages citing suspiciously precise side-effect percentages with no study or sample size behind them, and we have left those out because they appear fabricated. Read the consistency as the story the market tells itself, not as evidence any of it is right or safe. And none of it changes the core fact: a rise in growth hormone or IGF-1 is a biomarker moving, not a benefit anyone has shown in a person.

If you are going to explore it anyway, the harm-reduction version is straightforward: do it with a clinician who knows your cardiac and family history and can run baseline bloodwork, insist on a real certificate of analysis for the exact batch and confirm which form it actually is, and understand that you are the experiment, because the human data that would tell you whether this works, or is safe over time, does not exist. And if the honest answer for your situation is "not worth it," that is a legitimate place to land.

What the evidence implies clinically

By Dr. Sam Walters, NMD, Medical Director

CJC-1295 is sold with a confidence the human record does not earn. The human studies are real, and they are narrow: a few small trials showing the compound raises growth hormone and IGF-1 for several days in healthy adults. That is a laboratory result about a hormone level, not a finding that anyone grew stronger, leaner, or slept better, because those studies were never run.

The detail most people miss is which molecule they are actually buying: the no-DAC version on most shelves is not the form that was studied, so even the human numbers may not describe what is in the vial. And the one time the compound was given to patients for months rather than to volunteers for weeks, the program stopped after a death; the trial physician attributed it to pre-existing heart disease and judged it unrelated, but no one confirmed that independently and no results were ever published. A compound this popular and this lightly studied calls for caution rather than enthusiasm, and for most people the honest reading is "not from the evidence we have." That is the conversation I would want anyone to have with their own prescriber before deciding.

The honest close

For CJC-1295, the evidence supports a narrow, honest description and very little more: in healthy adults, the with-DAC form raises growth hormone and IGF-1 for several days, a biomarker effect, not a demonstrated benefit. There are no controlled human trials of muscle, fat, recovery, sleep, or aging; the body-composition data are from growth-hormone-deficient mice; the fat-reduction evidence people cite actually belongs to a different, approved drug; the form most people buy is the less-studied no-DAC version; the one multi-month patient program was halted after a death the trial physician judged unrelated; and it has never been approved and is banned in sport. For most people, the accurate read is "not from the evidence we have," and for athletes it is "not at all."

We do not prescribe, and we do not recommend a dose for you. We report what is actually done in research and practice and synthesize the evidence so you can have an informed conversation with your clinician, and when the honest read is "not yet" or "probably not worth it for you," we say so.

This content is for informational purposes and is not medical advice. Consult a licensed practitioner before changing any therapeutic protocol.

We don’t prescribe. We synthesize the research so you can have an informed conversation with your prescriber. And if the honest read of the evidence is “not yet” or “probably not worth it for you” — we’ll tell you that too.